دورية أكاديمية
Real-world effectiveness and factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia receiving remdesivir.
| العنوان: | Real-world effectiveness and factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia receiving remdesivir. |
|---|---|
| المؤلفون: | Quesada Muñoz L; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Fernández-Fradejas J; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Martinez-Barros H; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain hilario.martinez@salud.madrid.org., Sánchez Cuervo M; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Martín Rufo M; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Pintor Recuenco MDR; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Quereda Rodríguez-Navarro C; Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Álvarez-Díaz AM; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Saez de la Fuente J; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. |
| المصدر: | European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2023 Jun 20. Date of Electronic Publication: 2023 Jun 20. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101578294 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2047-9956 (Print) Linking ISSN: 20479956 NLM ISO Abbreviation: Eur J Hosp Pharm Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BMJ Publishing Group |
| مستخلص: | Objectives: Evidence on the effectiveness of remdesivir when used in real-life clinical practice is controversial. This study aims to analyse its effectiveness and the factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia who require supplemental low-flow oxygen and received remdesivir. Methods: A retrospective cohort study was conducted at Ramón y Cajal University Hospital (Madrid, Spain) which included all patients treated with remdesivir in our institution during the second pandemic breakout in Spain, from August to November 2020. Treatment with remdesivir was limited to non-critically ill patients with COVID-19 pneumonia requiring low-flow supplemental oxygen, with a treatment duration of 5 days. Results: A total of 1757 patients were admitted with COVID-19 pneumonia during the study period, of which 281 non-critically ill patients were treated with remdesivir and included in the analysis. Mortality at 28 days after initiation of treatment was 17.1%. The median (IQR) time to recovery was 9 days (6-15). 104 (37.0%) patients had complications during hospitalisation, with renal failure being the most frequent (31 patients; 36.5%). After adjustment for confounding factors, high-flow oxygen therapy was associated with increased 28-day mortality (HR 2.77; 95% CI 1.39 to 5.53; p=0.004) and decreased 28-day clinical improvement (HR 0.54; 95% CI 0.35 to 0.85; p=0.008). A significant difference in survival and clinical improvement was identified between patients treated with high and low-flow oxygen. Conclusion: The 28-day mortality rate in patients treated with remdesivir needing low-flow oxygen therapy was higher than that published in clinical trials. Age and increased oxygen therapy needed after the beginning of treatment were the main risk factors associated with mortality. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.) |
| فهرسة مساهمة: | Keywords: COVID-19; Communicable Diseases; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PULMONARY MEDICINE; VIROLOGY |
| تواريخ الأحداث: | Date Created: 20230620 Latest Revision: 20230620 |
| رمز التحديث: | 20230621 |
| DOI: | 10.1136/ejhpharm-2023-003729 |
| PMID: | 37339865 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2047-9956 |
|---|---|
| DOI: | 10.1136/ejhpharm-2023-003729 |